New Study Shows Tapering GLP-1 Drugs May Prevent Rebound Weight Gain
New research suggests that slowly tapering off GLP-1 drugs like Ozempic and Wegovy may help prevent rebound weight gain. A recent study revealed that patients who gradually reduced their dosage to zero were able to successfully maintain their weight. This innovative approach involved drug tapering and personalized holistic health coaching, emphasizing lifestyle modifications and behavioral changes for sustained weight loss.
Public Views and Usage of GLP-1 Drugs Revealed in Latest Health Tracking Poll
The latest KFF Health Tracking Poll reveals insights into public use and views of GLP-1 drugs, with 6% of adults currently using them for weight loss, diabetes, or heart disease. Despite increased awareness, affordability remains a concern, as 54% of adults find it challenging to cover costs. Usage is higher among adults with chronic conditions, highlighting accessibility and financial barriers faced by individuals seeking to benefit from GLP-1 drugs.
Metsera Emerges in Health and Medicine with Focus on Obesity Drug Development
Metsera, a new player in the health and medicine industry, is making waves in obesity drug development with a substantial $290 million in seed and Series A financing. Backed by top investment firms like Population Health Partners and ARCH Venture Partners, Metsera has strategically licensed drug candidates and assembled a team of industry veterans. With a diverse portfolio and significant funding, Metsera is set to revolutionize obesity treatment and carve out a promising future in the field of health and medicine.
Unexpected Pregnancies on Weight Loss Medications Lead to ‘Ozempic Babies’
Learn about the growing trend of ‘Ozempic babies’ as women share their experiences of unexpected pregnancies while on weight loss medications. Discover the challenges faced by women who abruptly stop these drugs to protect their unborn children, experiencing intense hunger and rapid weight gain. Experts suggest hormonal changes during pregnancy may exacerbate withdrawal effects, emphasizing the need for prompt consultation with doctors, especially for those using medications like Ozempic for diabetes treatment.
Promising Results in Slowing Parkinson’s Disease Progression
French researchers conduct a one-year study using a GLP-1 receptor agonist, a drug similar to Ozempic, showing promising results in slowing the progression of Parkinson’s disease. This development brings hope to the half a million Americans diagnosed with the illness and offers a glimmer of hope for individuals affected by Parkinson’s disease.
Understanding Ozempic: Mechanism of Action and Concerns
Learn everything about how Ozempic works, from its mechanism of action to its impact on weight loss. Understand its classification as a semaglutide and how it mimics a naturally occurring hormone to promote weight loss. Discover expert opinions on concerns over Ozempic usage and the emergence of a natural alternative, Berberine.
New Study Suggests Exercise Can Help Avoid Weight Regain After Stopping Weight Loss Drugs
Half of weight loss drug users stop treatment within a year, but a new study suggests exercise may prevent weight regain. GLP-1 receptor agonists like Ozempic can help patients lose 15% of body weight, but side effects lead to discontinuation. University of Copenhagen study found that those who exercised maintained weight loss, while those who didn’t regained 70% of lost weight, mostly in the form of fat.
FDA approves Novo Nordisk’s weight loss drug Wegovy for reducing cardiovascular risk
The FDA has approved Novo Nordisk’s weight loss drug, Wegovy, for reducing the risk of serious cardiovascular complications in adults with obesity and heart disease. This could expand insurance coverage for the drug, addressing a major barrier to patient access. Wegovy has been shown to reduce the overall risk of heart attack, stroke, and cardiovascular-related death by 20%, marking a significant milestone in public health for adults with obesity and heart disease.
Scrutiny over Restrictions on Weight-Loss Drugs Reveals Disparities in Obesity Care Coverage
Healthcare organizations and insurers are facing scrutiny over the restrictions placed on weight-loss drugs, shedding light on the disparities in obesity care coverage. The rise of highly effective weight-loss medications has brought attention to the unequal treatment of obesity within health plans, sparking initiatives like the EveryBODY campaign to advocate for comprehensive coverage. The debate surrounding coverage for obesity care has also been influenced by pharmaceutical companies, with some advocating for broader coverage to expand their customer base. Zeke Emanuel, a medical ethicist, highlighted the disparities in obesity care coverage as a reflection of deep-seated societal biases, emphasizing the need for a more equitable approach to obesity care coverage.
Woman’s Dangerous Weight Loss Attempt with Gray Market Semaglutide
A woman’s attempt to slim down for her wedding took a dangerous turn when she took gray market semaglutide, landing her in the emergency room. Despite severe stomach problems, she continued taking the drug to maintain her weight loss, only to wake up after her wedding with severe stomach pain and an infected appendix. This incident serves as a cautionary tale about the dangers of obtaining medications from unregulated sources and the potential risks associated with using them without medical supervision.